13F Holdings
中文EN

ARWR ARROWHEAD PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 879407 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.6%
TTM net income YoY-44,302.3%
TTM EPS YoY-51,000.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-156.9%
Net margin-160.6%
FCF margin-63.0%
EBITDA margin-151.4%

Returns

ROE-280.5%
ROA-46.4%
ROIC (approx.)-492.0%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets97.1%
Debt / equity0.00x
Current ratio4.14x
Interest coverage-7.55x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-29.0%
Payout ratio—
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-09-30FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30
Income statement
Revenue$450.82M$829.45M$3.55M$240.74M$243.23M
R&D expense$739.14M$607.16M$505.87M$353.19M$297.31M
SG&A expense$202.04M$123.94M$98.76M$92.55M$124.43M
Operating income-$707.17M$98.35M-$601.08M-$205.00M-$178.51M
Interest expense$93.71M$89.36M$32.35M$18.33M$0
Pretax income-$723.91M$51.53M-$612.46M-$206.49M-$172.71M
Income tax-$6.78M$21.42M-$2.77M$2.78M$3.79M
Net income-$724.21M-$1.63M-$599.49M-$205.28M-$176.06M
EBITDA-$682.47M$120.55M-$584.18M-$194.30M-$169.81M
EPS (basic)-5.11-0.01-5.00-1.92-1.67
EPS (diluted)-5.11-0.01-5.00-1.92-1.67
Weighted avg. shares (diluted)141.63M133.76M119.78M106.75M105.43M
Balance sheet
Cash & equivalents$62.73M$226.55M$102.69M$110.89M$108.00M
Short-term investments$1.13B$692.82M$578.28M$292.74M$0
Receivables$9.93M$6.82M$0$0$1.41M
Inventory$9.07M$0———
Current assets$1.29B$950.64M$695.47M$416.47M$405.30M
PP&E, net$371.31M$382.51M$386.03M$290.26M$110.30M
Intangibles$5.16M$6.86M$8.56M$10.26M$11.96M
Total assets$1.74B$1.39B$1.14B$765.55M$691.94M
Current liabilities$311.34M$195.49M$103.17M$105.46M$138.85M
Total liabilities$1.69B$881.88M$948.74M$478.39M$273.60M
Shareholders' equity$50.31M$466.05M$185.44M$271.34M$398.52M
Shares outstanding141.29M135.70M124.38M107.31M105.96M
Cash flow statement
Operating cash flow-$271.95M$179.55M-$462.85M-$153.89M-$136.13M
Capital expenditure$11.99M$22.67M$141.47M$176.74M$52.78M
Free cash flow-$283.94M$156.89M-$604.32M-$330.63M-$188.91M
Investing cash flow-$670.48M-$129.29M-$420.07M-$96.16M-$5.42M
Financing cash flow$776.82M$74.01M$870.52M$253.05M$65.19M
Depreciation & amortization$24.70M$22.20M$16.90M$10.70M$8.70M
Stock-based compensation$68.15M$63.37M$73.97M$78.13M$120.89M

Free plan shows the latest 5 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.